DE69032029T2 - Hybrides protein c - Google Patents

Hybrides protein c

Info

Publication number
DE69032029T2
DE69032029T2 DE69032029T DE69032029T DE69032029T2 DE 69032029 T2 DE69032029 T2 DE 69032029T2 DE 69032029 T DE69032029 T DE 69032029T DE 69032029 T DE69032029 T DE 69032029T DE 69032029 T2 DE69032029 T2 DE 69032029T2
Authority
DE
Germany
Prior art keywords
human
protein
modified
molecules
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69032029T
Other languages
English (en)
Other versions
DE69032029D1 (de
Inventor
Donald Foster
Richard Holly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of DE69032029D1 publication Critical patent/DE69032029D1/de
Application granted granted Critical
Publication of DE69032029T2 publication Critical patent/DE69032029T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69032029T 1989-12-29 1990-12-28 Hybrides protein c Expired - Fee Related DE69032029T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45885689A 1989-12-29 1989-12-29
US51537890A 1990-04-27 1990-04-27
PCT/US1990/007693 WO1991009960A1 (en) 1989-12-29 1990-12-28 Hybrid protein c

Publications (2)

Publication Number Publication Date
DE69032029D1 DE69032029D1 (de) 1998-03-12
DE69032029T2 true DE69032029T2 (de) 1998-08-20

Family

ID=27039137

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69032029T Expired - Fee Related DE69032029T2 (de) 1989-12-29 1990-12-28 Hybrides protein c

Country Status (11)

Country Link
US (1) US5766921A (de)
EP (1) EP0506821B1 (de)
JP (1) JP3270462B2 (de)
AT (1) ATE163048T1 (de)
AU (1) AU7168591A (de)
CA (1) CA2071630C (de)
DE (1) DE69032029T2 (de)
DK (1) DK0506821T3 (de)
ES (1) ES2113878T3 (de)
GR (1) GR3026414T3 (de)
WO (1) WO1991009960A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT397615B (de) * 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
SV1999000067A (es) * 1998-06-01 2000-07-06 Lilly Co Eli Proteina humana c polipeptida ref. x-12279
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
WO2000066754A1 (en) * 1999-04-30 2000-11-09 Eli Lilly And Company Protein c derivatives
EP1237917A2 (de) * 1999-11-19 2002-09-11 Eli Lilly And Company Derivate aus protein c
DE60108076T2 (de) * 2000-02-02 2006-03-16 Eli Lilly And Co., Indianapolis Protein c derivate
WO2001059084A1 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
WO2002032461A2 (en) * 2000-10-18 2002-04-25 Maxygen Aps Protein c or activated protein c-like molecules
EP1417055A4 (de) * 2001-07-19 2007-09-26 Dmi Biosciences Inc Verwendung von kupferchelatoren zur verhinderung der inaktivierung von protein c
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US20080305100A1 (en) * 2004-07-23 2008-12-11 Zlokovic Berislav V Activated Protein C Inhibits Undesirable Effects of Plasminogen Activator in the Brain
DE602005021509D1 (de) 2004-08-17 2010-07-08 Csl Behring Gmbh Modifizierte vitamin-k-abhängige polypeptide
US20110171200A1 (en) * 2008-01-15 2011-07-14 Walley Keith R Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711848A (en) * 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
US4902614A (en) * 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
ATE93272T1 (de) * 1985-06-27 1993-09-15 Zymogenetics Inc Expression von protein c.
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
EP0245949B1 (de) * 1986-04-09 1997-10-29 Eli Lilly And Company Verfahren zur Anwendung von den BK-Virus-Verstärker enthaltenden eukaryotischen Expressionsvektoren
DK323587D0 (da) * 1987-06-25 1987-06-25 Novo Industri As Protein
JPH03501921A (ja) * 1987-05-18 1991-05-09 インテグレイテッド・ジェネティクス・インク 改良タンパク質分子、並びにその製造及び活性化方法
EP0296413A2 (de) * 1987-06-12 1988-12-28 Hoechst Japan Limited Hybrides Protein C und Verfahren zur Herstellung
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
CA1340740C (en) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Co-expression in eukaryotic cells
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
JP2643968B2 (ja) * 1988-02-03 1997-08-25 サントリー株式会社 Ｋｅｘ２エンドプロテアーゼ及びその製造方法
JP2728240B2 (ja) * 1988-07-26 1998-03-18 ヘキスト薬品工業株式会社 ヒトプロテインｃ変異体及びその製造方法
JPH0246296A (ja) * 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインｃ及びその製造方法
FI85342C (fi) * 1989-02-03 1992-04-10 Tampella Oy Ab Foerfarande och anordning foer befuktning av partiklar i gasstroemningen.
DE69034013T2 (de) * 1989-03-06 2003-07-31 Univ Texas Serpin-resistenter T-PA; Mutanten; Gene
AU6295390A (en) * 1989-08-11 1991-03-11 Zymogenetics Inc. Cell culture methods for producing activated protein c

Also Published As

Publication number Publication date
US5766921A (en) 1998-06-16
WO1991009960A1 (en) 1991-07-11
GR3026414T3 (en) 1998-06-30
DE69032029D1 (de) 1998-03-12
ATE163048T1 (de) 1998-02-15
ES2113878T3 (es) 1998-05-16
AU7168591A (en) 1991-07-24
EP0506821A1 (de) 1992-10-07
EP0506821B1 (de) 1998-02-04
EP0506821A4 (en) 1992-11-04
JP3270462B2 (ja) 2002-04-02
DK0506821T3 (da) 1998-03-30
CA2071630C (en) 2000-02-22
CA2071630A1 (en) 1991-06-30
JPH06502986A (ja) 1994-04-07

Similar Documents

Publication Publication Date Title
DE69032029T2 (de) Hybrides protein c
MX9606386A (es) Agentes que afectan la hemostasis trombotica.
DE3484616D1 (de) Enzymwiderstandsfaehige immunomodulatorische peptide.
FI905956A (fi) Foerfarande foer producering av ett biologiskt aktivt protein.
DE69430253D1 (de) Komplement verwandte proteine und kohlenhydrate enthaltende zusammensetzungen und methoden zur herstellung und verwendung dieser zusammensetzungen
DE69128362T2 (de) Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit
EA199900464A1 (ru) Способы и композиции для стимуляции роста невритов
DE69736129D1 (de) Verfahren und Zusammensetzungen für die Behandlung von neoplastichen Krankheiten
DE60102147D1 (de) Anti-gefrier proteine, deren herstellung und verwendung
DE69510356D1 (de) Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie
DE60215649D1 (de) Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge
ATE251886T1 (de) Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
HU895788D0 (en) Process for producing peptides and medical products containing them
AR004093A1 (es) El uso de una proteina derivada de una quimioquina de mamifero y un medicamento util para movilizar celulas tronco hematopoyeticas.
ATE251640T1 (de) Neues chondrozytprotein
ATE85893T1 (de) Verwendung von somatostatin zur herstellung eines arzneimittels fuer die behandlung von rheumatoider arthritis.
DE69113049D1 (de) Varianten des gewebeplasminogenaktivators mit vermindertem abbau.
DE3485773T2 (de) Aus kultivierten mesenchymzellen extrahierte makromolekuele zur behandlung von degenerationskrankheiten.
ATE269090T1 (de) Tiermodell zum testen von arzneistoffen zur behandlung von leukämie oder hiv
BG60657B2 (en) Human recombinant interleukin-2 muteins
DE60326157D1 (de) Verfahren zur identifizierung von modulatoren der glucoseaufnahme

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee